Entry Point Capital, LLC Akebia Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
A detailed history of Entry Point Capital, LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 44,451 shares of AKBA stock, worth $75,566. This represents 0.05% of its overall portfolio holdings.
Number of Shares
44,451
Previous 40,996
8.43%
Holding current value
$75,566
Previous $149,000
19.46%
% of portfolio
0.05%
Previous 0.08%
Shares
3 transactions
Others Institutions Holding AKBA
# of Institutions
189Shares Held
121MCall Options Held
267KPut Options Held
280K-
Vanguard Group Inc Valley Forge, PA15.5MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA11.8MShares$20.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$19.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.18MShares$10.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$9.77 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $313M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...